Hematology disorders such as those caused by key plasma protein deficiencies that impede blood clotting or, conversely, result in excessive clotting, can result in serious medical complications or even death. Leveraging our experience in plasma-based clotting factors, Grifols is focused on widening our indication reach to help a larger number of patients living with these disorders.
Fostamatinib for chronic immune thrombocytopenia (ITP)
In people with ITP, the immune system attacks and destroys the body's own blood platelets, cells which play an active role in blood clotting and healing. Fostamatinib is the first new treatment for people with ITP in decades. It prevents the pathologic destruction of platelets by inhibiting a signaling cascade mediated by spleen tyrosine kinase (SYK).
Learn more about our approved fostamatinib treatment for ITP here.
A next-generation fibrinogen for severe fibrinogen deficiency
When fibrinogen, crucial for blood clotting, is either missing or does not function properly, the blood clot has difficulty forming, which can result in severe bleeding. Our Biotest group is investigating the use of its next-generation fibrinogen as a precision therapy to treat critical blood loss, such as during surgery or trauma, in patients with severe acquired fibrinogen deficiency, in addition to evaluating it for congenital fibrinogen deficiency.
Antithrombin III (AT-III) and intensive care
Grifols continues advancing in AT-III to ensure the right coagulation balance for patients, and is investigating the potential of this protein in a clinical trial to treat a life-threatening coagulopathy that results from sepsis. In the U.S., roughly 60% of sepsis cases become severe,1 with 30 to 50%2 of these severe sepsis patients experiencing disseminated intravascular coagulopathy (DIC). DIC involves excessive clotting in the bloodstream that can lead to massive bleeding elsewhere in the body and can lead to multiorgan failure.
Antithrombin limits the blood’s ability to clot by inhibiting thrombin, an enzyme that presides over the conversion of a substance called fibrinogen to fibrin, which promotes blood clotting. Its balance in plasma is key to avoiding too much clotting or bleeding issues. Our AT-III is the only plasma-derived medicine authorized and approved by the U.S. Food and Drug Administration to treat AT-III deficiency, an inherited blood-clotting disorder.
1 Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, Pinsky MR. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med. 2001;29(7):1303-1310.
2 Costello RA, Nehring SM. Disseminated Intravascular Coagulation. In: StatPearls. Treasure Island (FL): StatPearls Publishing; July 12, 2022.
KEY THERAPEUTIC AREAS
Patients are at the center of our far-ranging scientific research to develop therapeutic solutions to some of the world’s most pressing healthcare challenges.